Established in 2010, Solvotrin Therapeutics is seeking EII funding to launch its groundbreaking iron supplement in Europe next year, and in the United States the following year.
Chief executive Pat O’Flynn, a former Ernst & Young Entrepreneur of the Year finalist, said that Solvotrin Therapeutics’ primary focus is on “improving established therapies, making them better and safer, with the added advantage of patent protection linked to a defined market need”.
Subscribe from just €1 for the first month!
With any subscription you will have access to
Unlimited multi-device access to our iPad, iPhone and Android Apps
Unlimited access to our eReader library
Exclusive daily insight and opinion seven days a week
Create alerts to never miss a subject that matters to you
Get access to exclusive offers for subscribers on gifts and experiences
Get content from Business Post, Business Post Magazines, Connected, Tatler and Food & Wine
Crown Square campus shaping up to be proud achievement for Rhatigan
Galway city’s largest mixed-use development will incorporate the latest in low-carbon, high aesthetic design, set among landscaped plazas
Firms in south-west looking to a bright new future
Regional sales director of Close Brothers Commercial Finance Robert Keane sees confidence rise in local business as restrictions ease